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Over  the  past  year  huge  advances  have  been  made  in our ability  to  determine  the genetic  aetiology  of  many
neurological  diseases  through  the  utilisation  of  next  generation  sequencing  platforms.  This  technology  is,
on  a  daily  basis,  providing  new  breakthroughs  in  neurological  disease.  The  aim  of this  article  is  to clearly
describe  the  technological  platforms,  methods  of data  analysis,  established  breakthroughs,  and  potential
future  clinical  and  research  applications  of  this  innovative  and  exciting  technique  which  has  relevanceeywords:
xome
ext-generation
equencing
endelian
utation
to  all  those  working  within  clinical  neuroscience.
© 2012 Elsevier B.V. Open access under CC BY license.. Introduction
Progress in our understanding of the genetic basis of neu-
ological disease has expanded rapidly over the past 20 years.
hilst it is now clear that there is an extensive spectrum of
enetic involvement in the aetiology of neurological disease, the
ommon paradigm employed in most studies has been to essen-
ially divide the disorders into two dichotomous groups. Firstly,
common’ neurological diseases with complex phenotypes and
 probable multigenic component to their aetiology (such as
arkinson’s disease, multiple sclerosis and epilepsy), and sec-
ndly ‘rare’ neurological diseases which are perceived to have
 more narrow phenotype and obey strict Mendelian laws of
nheritance.
For the investigation of many common, complex diseases,
andidate gene and subsequent genome-wide association stud-
es (GWAS) have been widely adopted identifying an extensive
ist of loci associated with neurological disease [1–6]. Such
tudies have assisted in determining mechanisms of disease, how-
ver, most identiﬁed alleles are predicted to have a very small
ffect size [7], and infrequently lead to the discovery of causal
olymorphisms [8].
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Open access under CC BY license.Approaches to identify the genetic basis of rare Mendelian dis-
orders have advanced slowly but surely over the past decade, being
largely based on well-established techniques such as positional
cloning and linkage analysis followed by targeted candidate gene
screening. Cloning genes were critically dependent on identifying
large well-characterised pedigrees, groups of pedigrees with a pre-
sumed identical genetic aetiology, or consanguineous families with
a disease likely due to homozygous mutations. To some extent, ﬁnd-
ing the gene was  a matter of “luck”, based on the pedigree structure,
compounded by the cost and physical time taken to sequence a
large number of genes, which severely limited progress. As a result
the genetic basis of less than 50% of all Mendelian disorders has
been determined [9], and this has particular relevance in neurology.
For example, in the USA over half of patients recently recruited to
a national clinical programme tasked with determining the genetic
basis of rare diseases have neurological disorders; by far and away
the more prevalent specialty [10]. Our own  observations echo this
estimation, with approximately half of the patients in our neuroge-
netic clinic having no conﬁrmed molecular diagnosis (unpublished
observations).
However, this last year has seen a paradigm shift in the inves-
tigation of these rare Mendelian disorders, largely based on the
technical advance of a new DNA sequencing technology termed
‘next generation sequencing’ (NGS), also known as deep resequen-
cing, or massively parallel sequencing, which is revolutionising the
investigation of rare disorders [11]. NGS may  also enable the elu-
cidation of the contribution of rare alleles in common disorders,
potentially offering signiﬁcant breakthroughs in our understand-
ing.
M.J. Keogh, P.F. Chinnery / Clinical Neurology and Neurosurgery 115 (2013) 948– 953 949
F se bin
r tion re
l T).
a
i
d
2
a
D
t
u
F
l
f
a
tig. 1. (a) A DNA primer anneals to the template sequence of DNA. DNA polymera
andomly a ﬂuorescent labelled nucleotide in incorporated, and its chemical altera
ength (top to bottom in diagram) and the sequence is therefore determined (ATCA
The aim of this article is to review the most widely used
pproach, its role for rare Mendelian neurological disorders, and
ts potential for wider use across the continuum of neurological
isease.
. A new technique
Next  generation sequencing has been evolving since 2005 [12]
nd provides the ability to dramatically increase the speed at which
NA can be sequenced at a fraction of the cost of older sequencing
echnology. To illustrate this, in 2001 the Human Genome Project
sed ﬁrst generation Sanger sequencing technology to sequence
ig. 2. An example of two different DNA enrichment approaches though numerous met
igated to each end of the DNA (red lines). (c) Solid phase hybridisation occurs on a DNA
rom the exome but not intronic fragments of DNA which are washed away. Thereafter 
ttach to DNA fragments from the exome. Thereafter, streptavidin beads (black and grey c
o color in this ﬁgure legend, the reader is referred to the web version of the article.)ds incorporating free nucleotides into the DNA strand. The strand elongates until
sults in termination of the DNA strand. (b) DNA strands are read in order of chain
the  human genome, taking 13 years and $2.7 billion to achieve its
goal [13–15]. Next generation sequencing can now sequence an
individual genome in under 2 weeks for approximately US$ 4000,
representing remarkable progress.
However, based on current thinking, the whole genome does not
need to be sequenced to identify most human disease genes. Eighty-
ﬁve percent of pathogenic mutations causing Mendelian disorders
are found within the segments coding for proteins (exons) [16],
which collectively are referred to as the “human exome” [17]. This
dramatically cuts down the region that needs to be sequenced
in patients and families with undiagnosed neurogenetic disor-
ders, reducing the cost and time to approximately $1500 and 48 h
hods are available (a) DNA is randomly fragmented (black lines). (b) Adaptors are
 microarray. A collection of DNA spots/bait probes (blue line) bind to DNA regions
the exomic DNA is eluted. (d) Liquid phase hybridisation. DNA probes (blue lines)
ircles) are added to allow physical separation. (For interpretation of the references
950 M.J.  Keogh, P.F. Chinnery / Clinical Neurology and Neurosurgery 115 (2013) 948– 953
Fig. 3. Two common forms of DNA sequencing are shown. The process for one DNA fragment only is shown for clarity. (a) Top panel – DNA adaptors on a DNA fragment
bind to a complementary primer on a bead (bead – grey circle, primer – green line) which represents the 454 technique. (a) Bottom panel – DNA fragments are passed over a
lawn  of primers where they attach which represents the illumina (Solexa) technique. (b) In top and bottom panel, DNA is ampliﬁed many times so that multiple copies of the
fragment are on the bead (top panel) or in a cluster (bottom panel). The fragments are copied numerous times on each bead before being ﬁltered and the DNA denatured to a
single  strand and placed into a speciﬁc well (for the 454 technique), or remain in a speciﬁc channel on a slide for the illumina method. (c) Sequencing primers, polymerase and
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Ducleotides are added to the mix. As each nucleotide is added a laser activates a ﬂuo
ollowed  by a thymidine nucleotide. (d) Sensors detect the colour change from each
f the references to color in this ﬁgure legend, the reader is referred to the web ver
espectively. However, as discussed later, it is the bioinformatic
rocesses and data analysis of the DNA sequences which now pre-
ominantly inﬂuence the time taken to achieve a deﬁnitive result.
. So how does next generation sequencing work?
DNA sequencing was ﬁrst developed in 1975 by Sanger and Coul-
on [18] and his techniques are still used widely today. This ‘Sanger
equencing’ or ﬁrst generation sequencing, is based on the appli-
ation of oligonucleotide primers on either side of the desired DNA
equence followed by the addition of DNA polymerase and a mix-
ure of nucleotide “building blocks” enabling multiple copies of the
riginal DNA sample to be generated. The introduction of chain
erminating nucleotides in 1977 [19] enabled the generation of a
hole array of different copies of the original DNA sequence “chain
erminated” at all possible lengths, which are then separated out
n gel or capillary system by electrophoresis. Using known spe-
iﬁc labelled nucleotides (A, C, T or G) it is possible to assemble the
riginal DNA sequence (Fig. 1).
Next generation sequencing is based on the principle of mas-
ively parallel sequencing. This essentially means that thousands
r millions of pieces of DNA can be sequenced at the same time.
Initially  DNA is fragmented into multiple short segments called a
hotgun library. Adaptors are ligated to the ends of each fragment.
hese adaptors are short sequences of DNA which have priming
ites within them for the subsequent ampliﬁcation steps. The seg-
ents of DNA (complete with adaptors) are then mixed with probes
hich correspond to regions within the exome. The shotgun library
s then ‘enriched’ for the sequences of interest, using beads or a solid
late to allow physical separation of the exome from remaining
NA, and this is washed away. Custom arrays can be designed tonce, which is represented by incorporation of an adenine nucleotide and soon to be
or cluster with each nucleotide addition and the sequence read. (For interpretation
f the article.)
enrich  for speciﬁc groups of genes of interest, the whole exome,
and exon-ﬂanking regions (Fig. 2).
Following DNA enrichment, several manufacturers, each with
differing techniques provide next generation sequencing plat-
forms, the individual merits of which have been extensively
reviewed elsewhere [12]. Demonstrated in Fig. 3, however are two
of the most common forms of DNA sequencing technique, the illu-
mina (previously known as Solexa) and 454 method (also known
as Roche FLX) though several more exist. Brieﬂy, the 454 method
anchors DNA fragments to resin beads for ampliﬁcation before
transferring them into wells on a plate together with enzyme beads
for sequencing. The illumina method binds fragments to a slide
where DNA is ampliﬁed in clusters before sequencing takes place.
Several other methods also exist, and the techniques vary in DNA
fragment read length, time, cost and potential applications.
Once each segment of DNA is ampliﬁed and in situ on the slide
or plate, ﬂorescent nucleotides are added, together with DNA poly-
merase and sequencing primers. As ﬂuorescent tagged bases are
incorporated to each strand on each bead or channel, in real time,
laser activation of the ﬂuorescence can be read. Computers moni-
tor each cluster, and can determine the sequence of many clusters
at the same time (Fig. 3), and hence how sequencing data can be
generated at such a phenomenal rate.
4. Data processing
Whilst huge quantities of sequencing data can be produced rela-
tively quickly, the data analysis can be lengthy and difﬁcult. Taking
an individual case, whole exome sequencing will yield around
20,000–25,000 single nucleotide polymorphisms (SNPs) [20], and
determining which, if any represent a pathogenic mutation is dif-
ﬁcult. The approach to date has been for the sequences to ﬁrst
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ndergo a process called ‘discrete ﬁltering’. This entails cross-
eferencing the 20,000–25,000 or so polymorphisms with a set of
controls’, i.e. exome data from unaffected individuals. Such con-
rol data is publically available on databases such as dbSNP [21]
nd the 1000 genomes project [22], together with growing indi-
idual ‘in house’ exome control data sets generated within centres
sing exome sequencing. This step helps to ﬁlter out polymor-
hisms present within the local population, many of which are not
ecorded on public database. Cross referencing the patients SNPs
ith those in publically available databases assumes that mutations
een in the control data are not pathogenic (see later section for
ow this may  not be true), removing approximately 97–98% of the
olymorphisms, and leaving roughly 500–700 remaining [20,23].
The  next step is to further ﬁlter these remaining mutations.
irstly, those that do not ﬁt with the mode of inheritance (e.g.
eterozygous mutations in a presumed homozygous recessive dis-
ase) are removed, and then mutations are examined which occur
n genes known or predicted to have involvement in the biological
rocess or diseases with a similar phenotype. Candidate mutations
hich occur in a patient can also be checked to see if they segregate
ith disease phenotype in other family members, assuming appro-
riate samples are available. An additional stage often involves
he utilisation of new software tools which are now widely avail-
ble and help to determine which mutations may  have functional
mpact on the transcribed gene, are likely to be pathogenic muta-
ions, or are polymorphisms with no effect [24–26]. These packages
ssist with the ﬁltering process, however their results still need to
e interpreted in conjunction with the pedigree information and
iological signiﬁcance, and are not infallible.
The above description is an outline of the process for each
ndividual. Usually, several members of a family (affected and
naffected) will undergo exome sequencing when searching for a
ovel pathogenic mutation. For example sequencing two  distantly
elated relatives (e.g. cousins) within a phenotype, and cross-
eferencing their data can signiﬁcantly limit the potential candidate
utations to an even smaller number.
. Problems
There are of course limitations with exome sequencing, and they
an best be divided into ‘hardware’ and ‘software’ problems. The
ain ‘hardware’ problems arise through the incomplete enrich-
ent of the sequence of interest. For “whole exome” sequencing,
overage rates have improved from the 92% seen in initial studies
27], but achieving 100% coverage of the entire exome is still not
ossible. Secondly, it must be appreciated that coverage is not a
ichotomous concept. Coverage can be quantiﬁed in terms of depth,
hich is the average number of times a given DNA nucleotide is rep-
esented in sequence reads. If coverage is low, i.e. a particular base
s only covered 1 or 2 times/in 1 or 2 reads, then any sequencing
rror at that point could be interpreted as a mutation, or alterna-
ively a genuine mutation could be missed [28]. Thus, as part of the
equencing analysis it is important to be able to assess the exome
or regions of poor coverage which may  confound results.
Thirdly, to run the assay, several micrograms of DNA are
eeded. Whilst this is easily obtainable from a few millilitres of
lood, extracting enough DNA from limited and ﬁnite volumes of
tored tissue such as brain can prove difﬁcult. Finally, and perhaps
bviously, whole exome sequencing only sequences the exome,
ence pathogenic mutations in non coding regions which may
nclude vital regulatory regions and splice sites can exist and go
ndetected with exome sequencing. Such mutations are estimated
o cause disease in around 15% of all Mendelian disorders [16], and
t present whole genome sequencing would be needed to assist in
etecting these mutations.and Neurosurgery 115 (2013) 948– 953 951
Software, or ‘analytical’ challenges include difﬁculty in detec-
ting mutations such as repeat expansions. Despite recent studies in
amyotophic lateral sclerosis-frontotemporal dementia (ALS-FTD)
in which novel repeat expansions were detected with NGS [29],
exome sequencing is generally not useful for identifying repeat
expansions [23]. This limitation is particularly important in neurol-
ogy with many conditions such as Huntington’s disease, myotonic
dystrophy, Friedreich’s ataxia and forms of spinocerebellar ataxia
occurring due to trinucleotide repeat expansions [30,31] and hence
disorders with a similar genotypic abnormality may  not be detected
with exome sequencing.
Secondly,  although millions of sequences of DNA are produced,
they are relatively short, generally in the order of 25–350 bases
in length [12]. This creates problems when processing short reads
as many short sequences of DNA repeat themselves throughout the
genome, and hence they may be able to align at several positions. In
fact, about 15–20% of the short DNA reads cannot be unambiguously
mapped to a single location in the genome [32].
Thirdly, small base substitutions or insertions/deletions may  be
missed if the DNA in the sequence is slightly misaligned to the refer-
ence genome. Alignment difﬁculties can also create the impression
of new mutations that are not actually present in the original DNA
sequence [20].
Finally,  several pathogenic mutations are also present on pub-
lically available “control” databases, and may  be ﬁltered out of the
analysis at an early stage, “throwing out the baby with the bathwa-
ter”. These variants are present in the database for several reasons.
For example, many neurogenetic disorders present late in life, or
the diseases may  not be fully penetrant and therefore younger
patients or those who have not yet manifested the phenotype may
be included in reference data.
6. How may  exome sequencing help with neurological
disease?
In a research setting, exome sequencing is a potentially revo-
lutionary tool for the investigation of rare Mendelian disorders.
Putting the technical advantages already discussed aside, a key
strength of this technique is that it is able to detect new mutations
in an unknown gene in very small family pedigrees, and sometimes
only on one affected individual with a recessive disease. This simply
would not have been possible in the relatively recent past because
several affected individuals were needed to deﬁne a disease locus
through genetic linkage or homozygosity mapping. Finally, exome
sequencing can detect mutations in unexpected genes, broadening
the phenotype of a particular genetic disorder. This is not possible
with the candidate-gene based approach to diagnostics.
Data highlighting such advantages for neurological disease are
rapidly accumulating. For example, Wang et al. discovered a novel
mutation in the TGM6 gene as a cause of spinocerebellar ataxia
through exome sequencing. Linkage analysis using over 20 mem-
bers of the family had identiﬁed a relatively large region, consisting
of 91 genes in which the mutation was likely to be present.
Whole exome sequencing of just 4 patients in the family was able
to identify the mis-sense mutation in the TGM6 gene [33]. For
amyotrophic lateral sclerosis (ALS), exome sequencing with small
familial cohorts has also lead to revolutionary developments in our
understanding of the disease. In a study of 2 affected members of
an Italian family with an autosomal dominant pedigree of ALS, a
mutation of the VCP gene was identiﬁed and speculated to account
for 1–2% of all familial ALS [34]. More recently, the use of next gen-
eration sequencing lead to the ﬁnding of a hexanucleotide repeat
expansion in the C90RF72 gene, which the authors estimated to be
responsible for over 80% of familial ALS in Finland, and potentially
21% of sporadic ALS [29]. This highlights how using next generation
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equencing in small familial cohorts can lead to dramatic advances
or more prevalent diseases.
Exome sequencing for extremely rare neurological conditions
for example in which patients are isolated cases in their fami-
ies) has also been successful. Mutations in POLR3A and B encoding
NA polymerase subunits for example were shown to be the cause
f autosomal-recessive hypomyelinating leukoencphalopathy in a
tudy of 3 unrelated affected individuals [35]. Additionally, while
ot being able to ﬁnd a causative mutation, exome sequencing of 4
nrelated individuals with monomelic amyotrophy showed that
ariants of 2 genes (KIAA1377 and C5ORF42) increased the risk
f the disease signiﬁcantly (OR = 61.69) [36]. In non-neurological
onditions, 4 unrelated patients suffering from Schinzel–Giedion
yndrome, and 10 unrelated patients with Kabuki syndrome
nabled the identiﬁcation of novel mutations causative of these
onditions [37,38]. The difﬁculty however in using non-related
ndividuals is that there is signiﬁcant genetic heterogeneity
etween patients making it more difﬁcult to narrow the ﬁlter
o a causative mutation as discussed earlier. Additionally, whilst
atients with neurological conditions from different families may
e phenotypically similar, there is no guarantee they will harbour
he same mutation, or even that it will lie in the same gene, and
herefore looking for concordant mutations may  lead to inaccurate
esults.
The ability of the technique to detect mutations which were
ncongruous to the clinical phenotype is highlighted in a recent
tudy by Montenegro et al. In this study, exome sequencing was
erformed on two affected family members with an atypical phe-
otype of Charcot–Marie–Tooth disease (CMT). There was reported
ale–male inheritance in the family pedigree, however exome
equencing revealed an X-linked form of CMT  (GJB1 mutation),
hilst simultaneously excluding over 30 other known mutations
ausing CMT  [39].
.  Research applications for non Mendelian disorders
Whilst exome sequencing is now at the fore of research into
are Mendelian disorders, it is also likely to ﬁnd a key role in
he investigation of common, sporadic neurological conditions.
enome-wide association studies (GWAs) over the last 5–7 years
ave been the ‘modus operandi’ of research in this area, and have
ffered great insight into common variants associated with neuro-
ogical diseases such as multiple sclerosis, Alzheimer’s disease, and
pilepsy [1,40–44]. GWA  studies involve testing for up to a mil-
ion or more speciﬁc SNPs in each genome. The results are then
ompared between cohorts of affected individuals and unaffected
ontrols to see if any polymorphisms correlate with the disease
nd hence determined to be susceptibility loci. More recently, the
ocus of attention has been sub-phenotypes of disease, providing
he studies are adequately powered to address these issues. Using
hole exome sequencing it is possible to determine whether rare
lleles with a larger effect size contribute to the genetic landscape
f common diseases [45,46]. Truly large scale exome studies have
ot yet been published, but the application in sporadic disease has
lready been shown, where 20 unrelated patients with autism and
heir parents were exome sequenced, identifying 21 de novo muta-
ions, 11 of which were protein altering, offering new candidate
enes for the condition [47]. The importance of such studies are
hat they may  be able to detect low frequency variants with a high
elative risk, and additionally assist in characterising the regions
reviously suggested to be associated with disease from GWA  stud-
es [48]. However, as they are likely to detect de novo mutations,
uge numbers of samples will need to be included in such studies
o prove causation, and sequencing trios (i.e. an affected individual
nd their parents) will add to the cost.and Neurosurgery 115 (2013) 948– 953
8.  Clinical applications?
There  are also several potential clinical applications of exome
sequencing which are likely to be seen in neurological practice
within the next few years. The ﬁrst of these is the potential ability
to replace certain ‘panels’ of molecular genetic assays. For example,
the use of exome sequencing has recently been shown to be suit-
able to screen for the known mutations associated with hereditary
spastic paraplegias (HSP) and a selection of muscle disorders [49].
Similarly, for CMT, the ability with one sequencing run to test for
all known mutations (which currently number over 30) may  have
excellent diagnostic and ﬁnancial beneﬁts [39].
Whilst exome sequencing at present may  only be suitable for
screening phenotypes associated with signiﬁcant genetic hetero-
geneity (such as CMT  or HSP), with the number of genes associated
with numerous neurological conditions continuing to grow, test-
ing by way of exome sequencing may  become common. However,
caveats to this apply. As discussed earlier, exome sequencing at
present is not suitable to detect trinucleotide repeats, and hence
has limited value in detecting conditions such as myotonic dystro-
phy, fragile X-syndrome, and some forms of spinocerebellar ataxia
for example. It also has variable ability to detect copy number vari-
ations, hence having limited function to assess the PRKN and SNCA
genes in Parkinson’s disease [48,50].
An additional diagnostic beneﬁt is the ability to store the exome
sequencing data, and hence test for new mutations as they are dis-
covered, negating the need to repeatedly obtain and re-process
patient samples. However, the storage of highly detailed genetic
data also poses legal, logistical and ethical challenges. For exam-
ple, exome sequencing has already discovered mutations which
were not the desired focus of investigation when a mutation caus-
ing ciliary dyskinesia was discovered in a family undergoing exome
sequencing in investigation of Miller syndrome [51]. How we con-
sent and inform patients of the potential for such incidental ﬁndings
is a clinical and ethical challenge. Consideration of the consent pro-
cess to cover such situations in conjunction with the ethical issues
regarding the storage and sharing of highly personal information
needs careful consideration [52].
9. Conclusion
Exome sequencing is an exciting and extremely powerful tech-
nique which is currently revolutionising research in rare Mendelian
disorders. Its use is likely to eventually encompass the investiga-
tion of sporadic and common diseases, leading to the detection
of new causative mutations and association alleles which will
expand our understanding of neurological disease. Whilst whole
genome sequencing is likely to challenge its place at the fore of
neurogenetics over coming years, the basic science and clinical
information learnt from exome sequencing may rapidly reshape
research paradigms and facilitate future developments with whole
genome sequencing.
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